Table 2 Tumor response in each line of treatment
| Â | Total number | CR | PR | SD | PD | NE | ORR | DCR |
|---|---|---|---|---|---|---|---|---|
1st-line treatment | ||||||||
 All patients | 50 | 1 | 4 | 12 | 27 | 6 | 10.0% | 34.0% |
  Gemcitabine | 24 | 0 | 1 | 5 | 15 | 3 | 4.2% | 25.0% |
  S-1 | 12 | 0 | 0 | 5 | 6 | 1 | 0.0% | 41.7% |
  Gemcitabine plus nab-paclitaxel | 6 | 0 | 2 | 1 | 2 | 1 | 33.3% | 50.0% |
  Gemcitabine plus S-1 | 2 | 0 | 0 | 0 | 2 | 0 |  | |
  FOLFIRINOX | 2 | 0 | 1 | 0 | 1 | 0 | ||
  S-1 plus radiation | 1 | 0 | 0 | 1 | 0 | 0 | ||
  Paclitaxel | 1 | 1 | 0 | 0 | 0 | 0 | ||
  S-1 plus cisplatin | 1 | 0 | 0 | 0 | 1 | 0 | ||
  Gemcitabine plus radiation | 1 | 0 | 0 | 0 | 0 | 1 | ||
2nd-line treatment | ||||||||
 All patients | 13 | 0 | 1 | 4 | 4 | 4 | 7.7% | 38.5% |
  S-1 | 6 | 0 | 0 | 3 | 1 | 2 | 0.0% | 50.0% |
  Gemcitabine | 2 | 0 | 0 | 0 | 1 | 1 |  | |
  Gemcitabine plus nab-paclitaxel | 2 | 0 | 0 | 0 | 1 | 1 | ||
  FOLFIRINOX | 2 | 0 | 1 | 1 | 0 | 0 | ||
  FOLFOX | 1 | 0 | 0 | 0 | 1 | 0 | ||
3rd-line treatment | ||||||||
 All patients | 2 | 0 | 1 | 1 | 0 | 0 |  | |
  Gemcitabine | 1 | 0 | 0 | 1 | 0 | 0 | ||
  Gemcitabine plus nab-paclitaxel | 1 | 0 | 1 | 0 | 0 | 0 | ||
Cumulative total | ||||||||
 All patients | 65 | 1 | 6 | 17 | 31 | 10 | 10.8% | 36.9% |
  Gemcitabine | 27 | 0 | 1 | 6 | 16 | 4 | 3.7% | 25.9% |
  S-1 | 18 | 0 | 0 | 8 | 7 | 3 | 0.0% | 44.4% |
  Gemcitabine plus nab-paclitaxel | 9 | 0 | 3 | 1 | 3 | 2 | 33.3% | 44.4% |